HALOZYME THERAPEUTICS INC (HALO)
US40637H1095 - Common Stock
Halozyme to Report First Quarter 2024 Financial and Operating Results
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results...
NASDAQ:HALO is not too expensive for the growth it is showing.
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Notable Two Hundred Day Moving Average Cross - HALO
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
The 3 Best Biotech Stocks to Buy in Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech is an industry full of opportunity. It’s also known as one of the...
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.
First Week of May 17th Options Trading For Halozyme Therapeutics (HALO)
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
Halozyme to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...
Halozyme Therapeutics Breaks Above 200-Day Moving Average - Bullish for HALO
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing...
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and...
J&J seeks expanded FDA approval of Darzalex Faspro for multiple myeloma (NYSE:JNJ)
Johnson & Johnson (JNJ) said that it has submitted a supplemental Biologics License Application for approval of a Darzalex Faspro-based regimen for the treatmen
EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze (NASDAQ:HALO)
EU regulators approve Takeda's (TAK) Hyqvia, co-formulated with Halozyme's (HALO) Enhanze drug delivery technology, for the treatment of CIDP. Read more here.
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA®...
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell.
Johnson & Johnson wins arbitration appeal against Genmab
Genmab (GMAB) loses appeal in arbitration with J&J (JNJ) over multiple myeloma therapy Darzalex Faspro, but it won't impact the company's 2024 guidance. Read more here.